Get started
Author

Rajith K. R. Rajoli

Observed names: R. K. R. Rajoli, R. Rajoli, RKR Rajoli, Rajith K R Rajoli, Rajith K.R. Rajoli, Rajith KR Rajoli, Rajith Kumar Reddi Rajoli, Rajith Kumar Reddy Rajoli, Rajith Rajoli, Rajoli, RKR, Rajoli, Rajith K R, Rajoli, Rajith Kumar Reddy, Rkr Rajoli
ORCID: 0000-0002-6015-5712
Observed ORCID: 0000-0002-6015-5712
OpenAlex ID: A5085160612
Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics
2020 · Usman Arshad, Henry Pertinez, et al. · Clinical Pharmacology & Therapeutics · 158
PDF
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19
2021 · Carolina Q Sacramento, Natalia Fintelman-Rodrigues, et al. · Journal of Antimicrobial Chemotherapy · 102
PDF
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV
2014 · Rajith K. R. Rajoli, David J. Back, et al. · Clinical Pharmacokinetics · 96
Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis
2020 · Rajith KR Rajoli, Henry Pertinez, et al. · British Journal of Clinical Pharmacology · 62
PDF
Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK
2019 · Rajith K.R. Rajoli, Charles Flexner, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 52
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
2020 · Andrew V. Stachulski, Joshua Taujanskas, et al. · ACS Infectious Diseases · 49
Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling
2018 · Rajith K R Rajoli, Paul Curley, et al. · The Journal of Infectious Diseases · 48
PDF
Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico , In Vitro , and In Vivo Investigation
2016 · Paul Curley, Rajith K. R. Rajoli, et al. · Antimicrobial Agents and Chemotherapy · 37
PDF
The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2
2020 · Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 33
PDF
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2
2021 · Henry Pertinez, Rajith K R Rajoli, et al. · Journal of Antimicrobial Chemotherapy · 32
PDF
Physiologically‐Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir‐Boosted Lopinavir
2019 · Teerachat Saeheng, Kesara Na‐Bangchang, et al. · Clinical Pharmacology & Therapeutics · 31
PDF
In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
2017 · Rajith K. R. Rajoli, David J. Back, et al. · Clinical Pharmacokinetics · 31
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies
2019 · Shakir Adeyinka Atoyebi, Rajith K.R. Rajoli, et al. · European Journal of Pharmaceutical Sciences · 29
PDF
An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2
2021 · Lauren E. Walker, Richard FitzGerald, et al. · Clinical Pharmacology & Therapeutics · 27
PDF
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study
2018 · R. K. R. Rajoli, A. T. Podany, et al. · The International Journal of Tuberculosis and Lung Disease · 26
Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes
2016 · Catia Marzolini, Rajith Rajoli, et al. · Clinical Pharmacokinetics · 26
Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling
2019 · Fazila Bunglawala, Rajith K R Rajoli, et al. · Journal of Antimicrobial Chemotherapy · 23
A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo
2017 · Adny Henrique Silva, Enio Lima Jr, et al. · European Journal of Nanomedicine · 22
Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells
2022 · Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, et al. · Viruses · 19
PDF
Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach
2018 · Christina Y.S. Chan, Owain Roberts, et al. · Drug Metabolism and Pharmacokinetics · 19
PDF
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection
2021 · James J. Hobson, Alison C. Savage, et al. · Nanoscale · 18
PDF
Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding
2018 · Adeniyi Olagunju, Rajith K. R. Rajoli, et al. · AAS Open Research · 18
Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART
2017 · Owain Roberts, Rajith K R Rajoli, et al. · Journal of Antimicrobial Chemotherapy · 18
PDF
Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs
2016 · José Moltó, Rajith Rajoli, et al. · Journal of Antimicrobial Chemotherapy · 18
PDF
Development of a highly sensitive bioanalytical assay for the quantification of favipiravir
2021 · Paul Curley, Megan Neary, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 14
PDF
Works count: 63
Citation count: 1,165
H-index: 19
I10-index: 32
Year
Topic
Type